Top Markets
Coin of the day
Resverlogix Corp. Resverlogix Corp.

Resverlogix Corp.

RVX
주식 순위 #28673
Resverlogix Corporation is a biotechnology firm currently in advanced clinical... Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit bromodomain and extra-terminal proteins. This compound is presently undergoing pivotal Phase III clinical trials for patients afflicted with conditions such as cardiovascular disease, diabetes, various stages of kidney disease (including end-stage renal disease), and neurodegenerative disorders. Furthermore, Resverlogix Corp. has forged an alliance with Eversana Life Science Services, LLC to support the forthcoming commercial rollout of apabetalone as a treatment for COVID-19 across the United States and Canada. The company's main office is located in Calgary, Canada.
주가
$0.07339369
마지막 동기화: 2026-08-18
시가총액
$25.24M
변동 (1일)
5.26%
변동 (1년)
-9.55%
국가
CA
거래 Resverlogix Corp. (RVX)

카테고리

Resverlogix Corp. (RVX)의 주가 이력
최고 종가: $0.07 (2026-08-01 기준)

최저 종가: $1.62 (2004-05-01 기준)
Resverlogix Corp.의 주가 이력 (2004 ~ 2026)
연간 주가 성과
연도 성과
2026 (TTM) -6.81%
2025 102.06%
2024 -21.85%
2023 -56.62%
2022 -70.32%
2021 -46.30%
2020 -22.98%
2019 -58.94%
2018 55.79%
2017 15.32%
2016 3.07%
2015 197.15%
2014 -11.34%
2013 -71.83%
2012 26.66%
2011 -46.99%
2010 4.14%
2009 49.40%
2008 -88.69%
2007 34.88%
2006 78.65%
2005 76.80%
2004 0.00%
유사 기업 또는 경쟁사의 주가
회사 주가 변동률 1년% 국가
$552.07 41.28%
US
$168.77 504.69%
US
$1.03K 57.19%
NL
$117.42 -19.34%
AU
$753.28 8.59%
CH